CLDX - セルデックス・セラピュ―ティクス (Celldex Therapeutics Inc.) セルデックス・セラピュ―ティクス

 CLDXのチャート


 CLDXの企業情報

symbol CLDx
会社名 Celldex Therapeutics Inc. (セルデックス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セルデックス・セラピューティクス(Celldex Therapeutics Inc.)はバイオ医薬品会社である。同社はがんおよび他の疾患の治療のためのいくつかの免疫療法技術の開発・商業化に従事する。主薬のリンテカ(リンドペピムートおよびCDX-110とも呼ばれる)は、神経膠芽腫患者の治療のための治療的ワクチンである。そのグレムバツムマブベドチン(CDX-011とも呼ばれる)は、転移性メラノーマの治療のためのものである。バリルマブ(CDX-1127とも呼ばれる)は、免疫調節抗体である。臨床開発における早期段階の薬剤候補には、癌の適応症のための抗原提示細胞(APC)および免疫細胞動員剤および樹状細胞増殖因子であるCDX-301を標的とする標的免疫療法剤であるCDX-1401が含まれる。同社は多面的腫瘍関連マクロファージ(TAM)プログラムを含む。同社のパイプラインには、ヒト化モノクローナル抗体であるCDX-0158とCDX-3379を含む。   セルデックス・セラピュ―ティクスは、米国のバイオ医薬品企業。癌および治療が困難な疾患のための免疫療法技術の開発と商業化に従事する。薬剤候補は、「Rindopepimut(CDX-110)」免疫療法に標的を当てる、「Glembatumumab vedotin (CDX-011)」トリプルネガティブ乳癌治療のための薬などがある。   Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
本社所在地 Perryville III Building 53 Frontage Road Suite 220 Hampton NJ 08827 USA
代表者氏名 Larry Ellberger ラリー・エルバーガー
代表者役職名 Independent Chairman of the Board
電話番号 +1 908-200-7500
設立年月日 30651
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 197人
url www.celldex.com
nasdaq_url https://www.nasdaq.com/symbol/cldx
adr_tso
EBITDA EBITDA(百万ドル) -66.64400
終値(lastsale) 0.4326
時価総額(marketcap) 70272552.8232
時価総額 時価総額(百万ドル) 67.41357
売上高 売上高(百万ドル) 14.21100
企業価値(EV) 企業価値(EV)(百万ドル) -46.59543
当期純利益 当期純利益(百万ドル) -183.84300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Celldex Therapeutics Inc. revenues increased 27% to $6.8M. Net loss increased from $62.8M to $134.5M. Revenues reflect Revenue Sales of Goods_Services increase from $1.3M to $2.7M Contracts and Grants increase of 1% to $4.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.51 to -$0.95.

 CLDXのテクニカル分析


 CLDXのニュース

   Celldex Therapeutics Inc. (CLDX) Looks Set To Grow At A Great Clip In 2022  2022/04/06 12:00:00 Marketing Sentinel
Celldex Therapeutics Inc. (NASDAQ:CLDX) has a beta value of 2.76 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $1.68B, closed the last trade at $36.04 per share which meant it lost -$0.66 on the day or -1.80% during that session. The CLDX stock price is -58.71% … Celldex Therapeutics Inc. (CLDX) Looks Set To Grow At A Great Clip In 2022 Read More »
   Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/01 06:12:51 Seeking Alpha
   Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript  2022/03/01 01:57:16 Seeking Alpha
   Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M (NASDAQ:CLDX)  2022/02/28 21:02:32 Seeking Alpha
Celldex press release (NASDAQ:CLDX): Q4 GAAP EPS of -$0.43 misses by $0.02.Revenue of $0.33M (-91.3% Y/Y) misses by $0.84M.
   Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update  2022/02/28 21:01:00 GlobeNewswire
HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
   Celldex Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation  2022/03/01 06:12:51 Seeking Alpha
   Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 2021 Results - Earnings Call Transcript  2022/03/01 01:57:16 Seeking Alpha
   Celldex GAAP EPS of -$0.43 misses by $0.02, revenue of $0.33M misses by $0.84M (NASDAQ:CLDX)  2022/02/28 21:02:32 Seeking Alpha
Celldex press release (NASDAQ:CLDX): Q4 GAAP EPS of -$0.43 misses by $0.02.Revenue of $0.33M (-91.3% Y/Y) misses by $0.84M.
   Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update  2022/02/28 21:01:00 GlobeNewswire
HAMPTON, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.
   Celldex Q4 2021 Earnings Preview (NASDAQ:CLDX)  2022/02/27 22:35:00 Seeking Alpha
Celldex (NASDAQ:CLDX) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.36 and the consensus Revenue Estimate…
   The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself  2021/09/03 11:31:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE: ABT ) (announced acquisition of medical device company Walk Vascular) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Aug. 6) Axonics, Inc. (NASDAQ: AXNX ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bio-Techne Corporation (NASDAQ: TECH ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) (announced COO appointment) Cryo-Cell International, Inc. (NASDAQ: CCEL ) (announced uplisting to Nasdaq on Tuesday) DexCom, Inc. (NASDAQ: DXCM ) Edwards Lifesciences Corporation (NYSE: EW ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Erasca, Inc. (NASDAQ: ERAS ) Genmab A/S (NASDAQ: GMAB ) Globus Medical, Inc. (NYSE: GMED ) Intuitive Surgical, Inc.
   The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical  2021/08/31 12:05:06 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Techne Corporation (NASDAQ: TECH ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Clearside Biomedical, Inc. (NASDAQ: CLSD ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Dermata Therapeutics, Inc. (NASDAQ: DRMA ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Aug. 10) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) MiMedx Group, Inc. (NASDAQ: MDXG ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc.
   The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration  2021/08/27 11:35:25 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"
   The Daily Biotech Pulse: Early Approval For Ascendis'' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO  2021/08/26 12:09:13 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV ) BioLife Solutions, Inc. (NASDAQ: BLFS ) (reacted to the news of inclusion in the S&P SmallCap 600 Index) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Catalent Inc (NYSE: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Medtronic plc (NYSE: MDT ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 25) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Ascendis Gets FDA Nod For Pediatric Growth Hormone Deficiency Treatment Ascendis Pharma A/S (NASDAQ: ASND ) said the Food and Drug Administration has approved Skytrofa (lonapegsomatropin-tcgd) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone.
   Celldex EPS beats by $0.06, beats on revenue  2021/08/05 20:58:13 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セルデックス・セラピュ―ティクス CLDX Celldex Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)